Doctors no longer bound by noncompetes under FTC’s proposed ban
The FTC’s sweeping proposal would free physicians to work for a competitor, undermining the status quo in physician-employer relationships, attorneys told Healthcare Dive.
Hospitals disappointed with court ruling placing HHS in charge of 340B repayment
The court’s ruling on Tuesday is the latest update in a yearslong legal dispute between safety net hospitals and the government over payment rates.
Key trends for payers and providers in 2023
Providers are likely to clash with payers over rate hikes after a year of intense cost pressures.
Teladoc expects $2.4B in 2022 revenue, boosted by BetterHelp
BetterHelp’s contribution implies a growth rate of 43% for the business, up from previous management targets, according to an SVB Securities analyst.
CVS reportedly exploring $10B buy of Oak Street Health
Shares in Oak Street, which serves mostly seniors on Medicare, rose more than 32% in aftermarket trading following a Bloomberg report.
COVID-19 vaccine prices are going up. It shouldn’t be our focus.
Vaccinating as many people as possible to reduce the spread of respiratory illness that can be especially life-threatening for the youngest and oldest Americans is key, argues vaccine law professor Richard Hughes IV.
More than 7K New York nurses wage strike
Nurses at eight hospitals originally intended to strike. Ultimately, despite continued bargaining over the weekend, two failed to reach deals in time to stop nurses from walking off the job.
Rise of telehealth during pandemic boosted mental health treatment rates
The number of patients who received virtual care early in the pandemic surpassed those who dropped in-person mental health treatment in a new Rand study.
Sen. Bernie Sanders to target high healthcare costs as leader of influential committee
The longtime Congressman and “Medicare for All” proponent will soon assume leadership of the Senate HELP committee, giving him sway in one of the nation’s most broadly influential health policy platforms.
Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy
The pharma set the average annual cost of it and Biogen’s newly approved medicine Leqembi to $26,500, below the cost of the companies’ earlier drug Aduhelm but above one estimate of cost effectiveness.